Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.73 |
| ▸ | MAPT | P10636 | 7/20 | 0.64 |
| ▸ | RAB9A | P51151 | 6/20 | 0.64 |
| ▸ | NPC1 | O15118 | 4/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.62 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.61 |
| ▸ | APP | P05067 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3209559 | 1.00 | KDM4E (0.73) | KDM4EMAPTRAB9ANPC1NPSR1 | |
| SCHEMBL3210767 | 0.93 | MAPT (0.71) | KDM4EMAPTRAB9ANPC1NPSR1 | |
| SCHEMBL3210786 | 0.93 | MAPT (0.71) | KDM4EMAPTRAB9ANPC1NPSR1 | |
| SCHEMBL17003817 | 0.93 | KDM4E (0.64) | KDM4EMAPTRAB9ANPC1NPSR1 | |
| SCHEMBL16485478 | 0.93 | KDM4E (0.64) | KDM4EMAPTRAB9ANPC1NPSR1 | |
| SCHEMBL17691541 | 0.90 | MAPT (0.71) | KDM4EMAPTRAB9ANPC1APP | |
| SCHEMBL2730201 | 0.85 | KDM4E (1.00) | KDM4EMAPTRAB9ANPC1NPSR1 | |
| SCHEMBL2730205 | 0.85 | KDM4E (1.00) | KDM4EMAPTRAB9ANPC1NPSR1 | |
| SCHEMBL3211828 | 0.84 | MAPT (0.71) | KDM4EMAPTRAB9ANPSR1APP | |
| SCHEMBL3211852 | 0.84 | MAPT (0.71) | KDM4EMAPTRAB9ANPSR1APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8962674-B2 | Curcumin derivative | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2015-02-24 | — | — | US | disclosed |
| US-20100048901-A1 | NOVEL CURCUMIN DERIVATIVE | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2010-02-25 | — | — | US | disclosed |
| EP-2123637-A1 | NOVEL CURCUMIN DERIVATIVE | Tokyo Institute of Technology (JP) | 2009-11-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048901-A1 | NOVEL CURCUMIN DERIVATIVE | BACE1, APP, BACE2 | KDM4E 1141/4885MAPT 8/4885RAB9A 1684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.